« Return to News | CROs/Service Providers

PPD improves retention with PatientView portal

Monday, March 14, 2011 01:45 PM

CRO PPD seeks to improve patient retention in clinical trials by engaging participants more fully with the study process and information about their illness through a new online portal, according to Pharma Times.

Leveraging Microsoft HealthVault, a personal health application platform that allows users to gather, store and share health information online, PPD PatientView is a secure and customizable online portal linking clinical trial participants with biopharmaceutical companies, physicians and healthcare resources.

Participants can view, share and electronically archive medical information related to their illness, as well as communicate with the study team and stay connected with related activities, such as the trial registry and monitoring program. The PatientView technology allows patients access to the personal data they contribute to the study on a per-visit basis.

The rationale is to help clinical trial participants play a more active role in managing their own health while enhancing their sense of involvement and engagement in drug development. The consequence of that, PPD hopes, will be better retention rates.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.